Client(s) 苏州艾博生物科技有限公司
众达目前正作为艾博生物的法律顾问，就其与诺华达成旨在推进RNA编码疗法的许可及选择权协议的交易提供法律建议。该协议包括针对艾博生物的核心资产ABO2203（一款mRNA编码CD19xCD3 T细胞衔接器）的独家全球许可，以及关于数项基于艾博生物RNA平台开发的下一代疗法资产的独家许可选择权。
根据协议条款，艾博生物将获得5.75亿美元的首付款，同时，如果针对所有项目的选择权均被行使，且双方商定的开发、监管和商业里程碑均予达成，艾博生物还有资格获得最高约72亿美元的潜在里程碑付款。此外，艾博生物还有可能获得未来产品销售收入的潜在分成。
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice
